HK1083521A1 - Genes and polypeptides relating to human colon cancers - Google Patents

Genes and polypeptides relating to human colon cancers

Info

Publication number
HK1083521A1
HK1083521A1 HK06103520.7A HK06103520A HK1083521A1 HK 1083521 A1 HK1083521 A1 HK 1083521A1 HK 06103520 A HK06103520 A HK 06103520A HK 1083521 A1 HK1083521 A1 HK 1083521A1
Authority
HK
Hong Kong
Prior art keywords
genes
human colon
colon cancers
whose expression
polypeptides relating
Prior art date
Application number
HK06103520.7A
Other languages
English (en)
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29740821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1083521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1083521A1 publication Critical patent/HK1083521A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK06103520.7A 2002-06-06 2006-03-21 Genes and polypeptides relating to human colon cancers HK1083521A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38698502P 2002-06-06 2002-06-06
US41520902P 2002-09-30 2002-09-30
US45101303P 2003-02-28 2003-02-28
PCT/JP2003/007006 WO2003104275A2 (en) 2002-06-06 2003-06-03 Genes and polypeptides relating to human colon cancers

Publications (1)

Publication Number Publication Date
HK1083521A1 true HK1083521A1 (en) 2006-07-07

Family

ID=29740821

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103520.7A HK1083521A1 (en) 2002-06-06 2006-03-21 Genes and polypeptides relating to human colon cancers

Country Status (17)

Country Link
US (4) US7425612B2 (pt)
EP (3) EP1513934B1 (pt)
JP (3) JP4594085B2 (pt)
KR (2) KR101031025B1 (pt)
CN (1) CN100532549C (pt)
AT (1) ATE500326T1 (pt)
AU (2) AU2003241179C1 (pt)
BR (1) BRPI0311822B8 (pt)
CA (1) CA2488404C (pt)
CY (1) CY1112052T1 (pt)
DE (1) DE60336227D1 (pt)
DK (1) DK1513934T3 (pt)
HK (1) HK1083521A1 (pt)
MX (1) MXPA04012225A (pt)
PT (1) PT1513934E (pt)
SG (1) SG145559A1 (pt)
WO (1) WO2003104275A2 (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613406A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR100877554B1 (ko) * 2006-03-30 2009-01-07 재단법인 한국원자력의학원 간암 환자 생존기간 예측용 마커, 그를 포함하는 키트 및마이크로어레이, 및 상기 마커를 이용한 간암 환자생존기간 예측 방법
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US9045557B2 (en) 2009-03-18 2015-06-02 Oncotherapy Science, Inc. NEIL3 peptides and vaccines including the same
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2011336019B2 (en) * 2010-12-02 2016-07-07 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same
JP6038121B2 (ja) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
ES2968742T3 (es) * 2012-02-28 2024-05-13 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
CA2876517C (en) 2012-07-19 2019-01-08 Matthew Stuible Anti-siglec-15 antibodies
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
PL2906298T3 (pl) 2012-10-12 2019-04-30 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina - przeciwciało
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
CA2887894C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
ES2658888T5 (es) 2012-12-21 2021-10-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN103320445B (zh) * 2013-07-11 2017-07-28 重庆市肿瘤研究所 特异性识别胃癌细胞的dna适配子gca‑5及其应用
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
EP3494141A4 (en) 2016-08-03 2020-04-08 Bio-Techne Corporation IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
DK3544636T3 (da) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepin-antistof-konjugater
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
JP2021512120A (ja) * 2018-02-02 2021-05-13 バイオ−テクネ コーポレーション Ｖｉｓｔａとｖｓｉｇ３との相互作用を調節する化合物ならびにその製造および使用方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP2022538688A (ja) 2019-07-05 2022-09-05 イオックス セラピューティクス アーゲー ＩＧＳＦ１１（ＶＳＩＧ３）のＩｇＣ２に結合する抗体及びその使用
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000050588A2 (en) * 1999-02-22 2000-08-31 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055317A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20030228584A1 (en) * 2000-03-07 2003-12-11 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001245280A1 (en) * 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001296301A1 (en) * 2000-09-26 2002-04-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
WO2003027228A2 (en) * 2001-07-17 2003-04-03 Incyte Genomics, Inc. Receptors and membrane-associated proteins
JP2003245084A (ja) * 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途

Also Published As

Publication number Publication date
CA2488404A1 (en) 2003-12-18
JP5069268B2 (ja) 2012-11-07
BRPI0311822B8 (pt) 2021-05-25
MXPA04012225A (es) 2005-07-25
US7847065B2 (en) 2010-12-07
US7425612B2 (en) 2008-09-16
AU2003241179C1 (en) 2010-11-25
JP2006507802A (ja) 2006-03-09
JP2012019791A (ja) 2012-02-02
ATE500326T1 (de) 2011-03-15
CN1675361A (zh) 2005-09-28
CY1112052T1 (el) 2015-11-04
KR20050053530A (ko) 2005-06-08
CA2488404C (en) 2012-11-27
KR20100123761A (ko) 2010-11-24
KR101031025B1 (ko) 2011-04-25
EP2233572A2 (en) 2010-09-29
CN100532549C (zh) 2009-08-26
WO2003104275A2 (en) 2003-12-18
AU2003241179B2 (en) 2009-09-03
US7705141B2 (en) 2010-04-27
US20100016220A1 (en) 2010-01-21
DE60336227D1 (de) 2011-04-14
SG145559A1 (en) 2008-09-29
EP1513934A2 (en) 2005-03-16
BRPI0311822B1 (pt) 2019-10-29
DK1513934T3 (da) 2011-05-02
KR101077177B1 (ko) 2011-10-27
US20050069930A1 (en) 2005-03-31
PT1513934E (pt) 2011-05-11
US20120190628A1 (en) 2012-07-26
EP2275544A3 (en) 2011-03-30
EP2275544A2 (en) 2011-01-19
EP2233572A3 (en) 2011-01-12
JP2009183293A (ja) 2009-08-20
US20090012032A1 (en) 2009-01-08
WO2003104275A3 (en) 2004-04-15
JP4594085B2 (ja) 2010-12-08
BR0311822A (pt) 2005-03-29
AU2003241179A1 (en) 2003-12-22
EP1513934B1 (en) 2011-03-02
AU2009243506A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
HK1083521A1 (en) Genes and polypeptides relating to human colon cancers
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
WO2003104276A3 (en) GENES AND POLYPEPTIDES RELATED TO HEPATOCELLULAR OR COLORECTAL CARCINOMA
Krause Therapy across culture.
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
ATE406906T1 (de) Von survivin abstammende peptide und deren verwendung
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
HUP0302824A2 (hu) Vakcinakészítmények
DE69936780D1 (de) Antikörper gegen eine lar-phosphatase untereinheit
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
DE3751809T2 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
TR200200912T2 (tr) APRIL (çoğalma uyarıcı ligand) reseptörü (BCMA) ve kullanımları
WO2006016525A3 (en) Genes and polypeptides relating to breast cancers
CY1109125T1 (el) Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
TW200502247A (en) Genes and polypeptides relating to human colon cancers
WO2002064023A3 (en) Fra-1 expression in brain cancer
WO2007013479A3 (en) Genes and polypeptides relating to prostate cancers
EP2293065A3 (en) Methods and compositions for diagnosing hepatocellular carcinoma
AU2001255734A1 (en) Sigma-2 receptors as biomarkers of tumor cell proliferation
TH82888A (th) ยีนและโพลีเปปไทด์ที่เกี่ยวข้องกับมะเร็งลำไส้ใหญ่คน
Fujishiro et al. Metachronous multiple esophageal cancers and a gastric cancer after treatment for hypopharyngeal cancer, report of a case

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE CHINESE NAME OF THE APPLICANT

Effective date: 20101125

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220603